

Claim Summary

1 – 23 (canceled)

24. (new) A compound which is (+) or (-)-1-[2-(2-ethoxyphenyl)-1-phenylethyl]piperazine, or a pharmaceutically acceptable salt thereof.

25. (new) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in claim 24 and a pharmaceutically acceptable adjuvant, diluent or carrier.

26. (new) A method of treatment of a disorder in which the regulation of serotonin or noradrenaline is implicated which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 24 to a patient in need of such treatment.

27. (new) A method according to Claim 26, wherein the regulation of serotonin and noradrenaline is implicated.

28. (new) A method of treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia, which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 24 to a patient in need of such treatment.

29. (new) A method according to Claim 28, wherein the urinary disorder is urinary incontinence.

30. (New). A method according to Claim 29, wherein the urinary disorder is genuine stress incontinence or stress urinary incontinence.